Sanofi and Luminostics to create cell-phone based test for Covid-19 Kumar Jeetendra | April 18, 2020 Sanofi has started working with California startup Luminostics to construct an at-home test for COVID-19 that would utilize an example peruser fueled by a client’s close to home cell phone. Utilizing a connector that cuts via telephone’s camera and flashbulb, Luminostics’ minimal effort, reusable gadget contains synthetic substances that faintly shine in obscurity when certain …
Aurobindo Pharma gets VAI arrangement from US controller for Hyderabad unit Kumar Jeetendra | April 22, 2020 Aurobindo Pharma on Tuesday said the US health controller has concluded that the examination arrangement of organization’s injectable detailing fabricating office at Hyderabad is voluntary action indicated (VAI). According to the USFDA, a VAI assessment grouping demonstrates that despite the fact that specialists found and recorded offensive conditions during the examination, FDA won’t make or …
Lincoln Pharma gets Gujarat food and drug controller gesture to make HCQ tablets Kumar Jeetendra | April 27, 2020 Lincoln Pharmaceuticals hit an upper circuit breaking point of 5% at Rs 152.70 after the organization said it got endorsement to fabricate Hydroxychloroquine and Hydroxychloroquine Sulfate tablets to battle Covid-19. Lincoln Pharmaceuticals reported during exchanging hours today, 27 April 2020, that it has gotten endorsement to make Hydroxychloroquine (HCQ) among other basic medications to battle …
USFDA licenses emergency utilization of medication for treating COVID-19 patients Kumar Jeetendra | May 2, 2020 US controllers on Friday permitted crisis utilization of an exploratory medication that seems to help some coronavirus patients recuperate quicker. It is the primary medication appeared to help battle COVID-19, which has slaughtered in excess of 230,000 individuals around the world. The Food and Drug Administration acted after starter results from a legislature supported examination …
India lifts trade prohibition on Trump-touted medicate hydroxychloroquine Kumar Jeetendra | June 11, 2020 U.S. President Donald Trump as a potential “distinct advantage” in the battle against the COVID-19 pandemic, a priest said late on Wednesday. “Division of Pharmaceuticals has affirmed the lifting of restriction on Export of Hydroxychloroquine API just as definitions,” India’s clergyman for synthetic concoctions and manures, Sadananda Gowda, said on Twitter. Makers, with the exception …
India’s Hetero Labs wins endorsement to dispatch COVID-19 medication favipiravir Kumar Jeetendra | July 29, 2020 India’s Hetero Labs Ltd said on Wednesday it received neighborhood regulatory approval to start its own version of antiviral medication favipiravir for the treatment of COVID-19. The drug, priced in 59 rupees (79 cents) each tablet, will probably be Available at drug stores from Wednesday, independently held Hetero explained.
The need to combat antimicrobial resistance Kumar Jeetendra | August 5, 2020 With over 700,000 people losing the battle to antimicrobial resistance (AMR) every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, antibacterial resistance (ABR) is currently posing serious challenges to medical science. Facets driving …
What have we learned from the nitrosamine crisis? Kumar Jeetendra | May 8, 2021 The pharmaceutical industry is facing an ongoing issue with genotoxic impurities (GTIs). Over the past year, we have witnessed genotoxic impurities affect several drugs, including those used to treat elevated blood pressure, heartburn and acid reflux. Angiotensin II receptor blockers (including valsartan, losartan and irbesartan), along with ranitidine and nizatidine, were recalled to investigate several …
Alembic Pharmaceuticals’ Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, gain USFDA approval. Kumar Jeetendra | January 6, 2023 06th January 2023, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Toviaz Extended-Release …
